Post-earnings recap
Reported
Mon, Aug 11, 2025
EPS actual
$-0.72
EPS est.
$-0.74
EPS surprise
+2.83%
1-day move
-0.29%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a wider-than-expected loss per share but did not provide revenue figures. The stock reacted with a slight decline of 0.29%, reflecting investor caution amid the lack of revenue data and guidance. Management's commentary suggests they are focused on long-term goals despite current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.72 | N/A | +2.83% |
| Revenue | N/A | N/A | N/A |
Management remains focused on their research pipeline and future opportunities. They acknowledged the current financial performance but expressed optimism about upcoming developments.
Management highlighted ongoing research efforts and future potential.
They emphasized the importance of long-term goals despite current challenges.